LAX.SH
PANACEA BIOTEC LTD·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
411.1
-0.62%52W Range
Market Cap
₹2,518.02 Cr
Traded: ₹5.20 Cr (0.21%) 0.0x
Free Float: ₹603.32 Cr (0.86% of FF traded)
Volume · 60D trend
1.27 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +0.0% | +0.0% | +12.0% | -- | +14.0% | Accelerating |
| Profit | +5.0% | +13.0% | +21.0% | -- | +52.0% | Accelerating |
| Return | +14.0% | +0.0% | +51.0% | -22.0% | -- | Stable |
| ROE | -- | -10.0% | -3.0% | -- | -- | Accelerating |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 200 | 167 | 165 | 141 | 167 | 133 | 163 | 147 | 116 | 136 | 151 | 143 | 129 | 129 | 115 | 105 |
| Expenses | 194 | 164 | 153 | 159 | 168 | 159 | 156 | 140 | 130 | 143 | 151 | 147 | 140 | 135 | 124 | 109 |
| Operating Profit | 6 | 3 | 12 | -18 | -1 | -27 | 8 | 7 | -14 | -6 | -0 | -4 | -10 | -6 | -9 | -4 |
| OPM % | 2.8% | 1.5% | 7.1% | -12.6% | -0.7% | -20.3% | 4.9% | 4.8% | -12.1% | -4.4% | -0.1% | -2.5% | -8.0% | -4.4% | -7.5% | -4.0% |
| Other Income | 7 | 5 | 5 | 9 | 17 | 36 | 6 | 7 | 7 | 14 | 8 | 6 | 34 | 34 | 42 | 38 |
| Interest | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 10 |
| Profit Before Tax | 4 | -1 | 6 | -19 | 7 | -0 | 4 | 5 | -17 | -2 | -2 | -8 | 13 | 18 | 22 | 23 |
| Tax % | 38.4% | -20.0% | 40.1% | -26.9% | 39.6% | 4875.0% | -1.4% | 1.1% | -6.9% | -6.1% | 33.3% | 6.6% | 15.7% | 169.6% | 13.7% | 33.0% |
| Net Profit | 2 | -1 | 4 | -14 | 4 | -2 | 4 | 5 | -16 | -2 | -2 | -8 | 11 | -13 | 19 | 16 |
| Exceptional Items | -- | 3 | 3 | 3 | 11 | 28 | 3 | 3 | 3 | 3 | 3 | 3 | 28 | 19 | 28 | 28 |
| EPS (Rs) | 0.4 | 0.1 | 0.7 | -2.3 | 0.7 | -0.3 | 0.7 | 0.8 | -2.6 | -0.3 | -0.4 | -1.4 | 1.8 | -2.1 | 3.2 | 2.6 |
| Sales Growth (YoY) | 19.7% | 25.8% | 1.0% | -4.2% | 44.0% | -2.9% | 8.6% | 3.0% | -10.4% | 5.8% | 30.6% | 36.0% | 16.7% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 0.9% | 17.1% | -15.3% | 25.8% | -18.9% | 10.9% | 27.3% | -15.2% | -9.3% | 5.2% | 10.7% | 0.2% | 11.9% | 9.7% | -- |
| OP Growth (YoY) | 580.5% | 109.6% | 47.5% | -354.1% | 91.6% | -345.0% | 5406.7% | 296.6% | -35.7% | -6.5% | 98.3% | 11.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 120.6% | -78.1% | 166.0% | -1407.6% | 95.6% | -437.7% | 13.7% | 150.0% | -131.6% | -3926.7% | 95.8% | 65.5% | -81.8% | 34.4% | -116.0% | -- |
| Profit Growth (YoY) | 113.0% | 93.0% | 33.0% | -906.0% | 75.0% | -466.0% | 139.0% | 119.0% | -26.0% | -298.0% | 17.0% | -144.0% | 82.0% | 96.9% | 89.2% | 92.0% |
| EPS Growth (YoY) | -- | 125.8% | -12.2% | -391.0% | 125.6% | 3.1% | 300.0% | 157.8% | -244.1% | 84.5% | -111.7% | -152.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -87.7% | 128.6% | -443.9% | 312.9% | -141.9% | -5.1% | 130.2% | -706.3% | 13.5% | 72.6% | -175.4% | 186.5% | -165.5% | 23.4% | -- |
| OP Margin | -- | 1.5% | 7.1% | -12.6% | -0.7% | -20.3% | 4.9% | 4.8% | -12.1% | -4.4% | -0.1% | -2.5% | -8.0% | -4.4% | -7.5% | -3.8% |
| Net Margin | -- | -0.6% | 2.4% | -9.9% | 2.4% | -1.5% | 2.7% | 3.2% | -13.7% | -1.5% | -1.5% | -5.8% | 8.5% | -9.8% | 16.8% | 15.2% |
| Material Cost % | -- | 45.8% | 41.1% | 41.8% | 46.3% | 39.3% | 38.3% | 29.3% | 36.0% | 36.5% | 44.7% | 40.7% | 42.5% | 44.6% | 41.5% | 34.7% |
| Employee Cost % | -- | 28.1% | 24.5% | 33.8% | 27.4% | 37.1% | 26.3% | 29.5% | 32.4% | 28.2% | 25.0% | 26.2% | 27.8% | 23.7% | 27.8% | 30.3% |
| P/S | 3.74 | 3.97 | 4.18 | 3.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.02 | 3.04 | 3.06 | 2.45 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed newspaper copies of the public notice, requesting shareholders to register their email addresses with the Company in connection with ensuing AGM of the Company.
Please find attached of the extract of statement of Unaudited Financial Results for the quarter ended 30.06.2026, published on 14.08.2026.
Please find attached Unaudited Financial Results for quarter ended June 30, 2026.
Please find attached Outcome of Board Meeting held on August 13, 2026.
Please find attached newspaper copies regarding notice intimating the investors about the opening of Special Window for transfer and dematerialisation of physical shares.
Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
The Company''s wholly owned subsidiary, Panacea Biotec Pharma Ltd. has received a Show Cause Notice (SCN) dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services ....
We would like to inform you that the Company has on July 16, 2026, filed appeal before the Hon''ble High Court of Punjab and Haryana, Chandigarh, against the remaining 4th award. The ....
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Please find attached disclosure which is self explanatory
We would like to inform that no share has been dematerialised during June 2026. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd. ....
Please find attached certificate dated July 01, 2026, issued by Skyline Financial Services Pvt. Ltd. , RTA under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, ....
We would like to inform you that the trading window of the Company shall remain closed from July 01, 2026 till completion of 48 hours from the announcement of the Unaudited financial results ....
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Rajesh Jain
Please find attached newspaper copies regarding notice intimating the investors about the opening of a special window for transfer and dematerialisation of physical shares.
Panacea Biotec is pleased to inform the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa (sSA) and to facilitate ....
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Please find attached details of shares dematerialised during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Please find attached copies of newspaper publication of Audited Financial Results for the quarter and financial year ended March 31, 2026.
Please find attached results
We would like to inform you that the Board of Directors has at its meeting held today i.e. 30.05.2026 approved the appointment of Mr. Rajinder Singh Manku as an additional director in the ....
We would like to inform you that the Board of Directors has at its meeting held today, i.e. Saturday, May 30, 2026, inter-alia, considered and approved: 1. the Standalone and Consolidated ....
Please find enclosed Secretarial Compliance Report duly issued by R&D Company Secretaries, Practicing Company Secretaries for the financial year ended March 31, 2026.
We would like to inform you that the Board of Directors of the Company''s material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 29.05.2026 , inter-alia, ....
The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 29/05/2026 has been revised to 30/05/2026
Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Please find enclosed herewith the details of shares dematerialised during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
This is to inform you that a fire incident occurred on 30.04.2026 due to short circuit at the Oncology Control Laboratory of the Company''s wholly owned subsidiary, Panacea Biotec Pharma ....
We would like to inform you that the Income Tax Appellate Tribunal ("ITAT") vide its Order dated 29.04.2026, allowed the appeal filed by the Company and set aside the Order dated 14.08.2025 ....
Please find enclosed herewith newspaper copies regarding notice intimating the investors about the opening of Special Window for Transfer and Dematerialisation of physical shares, in accordance ....
We are delighted to inform you that Panacea Biotec Ltd. has received a Letter of Award dated 10.04.2026 from Central Medical Services Society, Ministry of Health and Family Welfare, Government ....
We would like to inform you that the Company has received four Awards from the Presiding Officer (in the rank of Additional District Judge) of Industrial Tribunal, S.A.S. Nagar, Mohali. A ....
We are enclosing herewith a certificate dated 01.04.2026, issued by Skyline Financial Services Pvt. Ltd., Registrar and Transfer Agent of the Company, confirming compliance under Regulation ....
In continuation to our letter dated 02.03.2026, we are pleased to inform you that the Deputy Commissioner of Income Tax has issued a rectified Assessment Order dated 06.04.2026. Under this ....
In continuation to our letter dated 06.03.2026, we are pleased to inform you that Deputy Commissioner of Income Tax has issued a rectified Assessment Order dated 06.04.2026. Under this ....
We would like to inform you that no share has been dematerialised during the month of March 2026. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services ....
We would like to inform you that Mr. Mukul Gupta (DIN: 00254597), Independent Director of the Company has completed his second and final term of 5 consecutive years as Independent Director ....
We would like to inform you that Mr. Mukul Gupta (DIN: 00254597), Independent Director of the Company has completed his second and final term of 5 consecutive years as Independent Director ....
We would like to inform you that the Company has received a Demand Order dated 30.03.2026 from the Office of the Joint Commissioner, CGST Sub- Commissionerate Mohali, Chandigarh under CGST ....
We would like to inform you that CA Rajesh Jain, Independent Director of the Company and its material wholly owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") vide his e-mails dated ....
We would like to inform you that with respect to the appeals filed by the Company in the Office of the Commissioner of Income Tax (Appeals), New Delhi ("CIT(A)"), against the Penalty Orders ....
We would like to inform you that the trading window of the Company shall remain closed for all the Designated Persons (including their immediate relatives) of the Company from April 01, ....
We are pleased to inform you that the Company''s wholly owned subsidiary, Panacea Biotec Pharma Ltd. (PBPL) has received an Order dated 10.03.2026 issued by the Deputy Commissioner of State ....
We are pleased to inform you that with respect to the appeals filed by the DCIT / Panacea Biotec Ltd. during Financial year 2015-15, the Company has received on 10.03.2026, an order dated ....
Please find enclosed herewith demat status report for the month of February 2026.
We would like to inform you that the Company has received on March 06, 2026, a Demand Order dated March 01, 2026, from the Office of Deputy Commissioner of Income Tax, imposing demand on ....
We would like to inform you that the Company has received on 01.03.2026, a Demand Order dated 27.02.2026, from the Office of Deputy Commissioner of Income Tax, Delhi imposing demand on ....
Please find enclosed herewith newspaper copies regarding notice intimating the investors about the opening of special window for transfer and dematerialisation of physical shares, published ....
Please find enclosed herewith newspaper copies of the Extract of Statement of Unaudited Financial Results for quarter and nine months ended 31.12.2025.
We would like to inform you that the Board of Directors has in its meeting held today i.e. 11.02.2026, inter-alia considered and approved the Standalone and Consolidated Unaudited Financial ....
Annual Reports
14Credit Ratings
6Held by ETFs
1 ETFs hold panaceabio · sorted by weight
Held by Mutual Funds
1 schemes hold panaceabio · sorted by weight